Menu
Search
|

Menu

Close
X

Atara Biotherapeutics Inc ATRA.OQ (NASDAQ Stock Exchange Global Select Market)

44.80 USD
-- (--)
As of Feb 20
chart
Previous Close 44.80
Open --
Volume --
3m Avg Volume 153,719
Today’s High --
Today’s Low --
52 Week High 49.90
52 Week Low 11.80
Shares Outstanding (mil) 37.60
Market Capitalization (mil) 1,684.30
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.14 Mean rating from 7 analysts

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
0
FY15
0
EPS (USD)
FY17
-2.841
FY16
-2.750
FY15
-2.211
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
35.76
Price to Sales (TTM)
vs sector
--
8.59
Price to Book (MRQ)
vs sector
6.66
5.23
Price to Cash Flow (TTM)
vs sector
--
26.13
Total Debt to Equity (MRQ)
vs sector
0.00
15.32
LT Debt to Equity (MRQ)
vs sector
0.00
11.95
Return on Investment (TTM)
vs sector
-42.33
13.59
Return on Equity (TTM)
vs sector
-43.02
15.20

EXECUTIVE LEADERSHIP

Isaac Ciechanover
Chairman of the Board, President, Chief Executive Officer, Since 2016
Salary: $546,000.00
Bonus: $327,870.00
John McGrath
Chief Financial Officer, Executive Vice President, Since 2014
Salary: --
Bonus: --
Joseph Newell
Executive Vice President, Chief Technical Operations Officer, Since 2017
Salary: --
Bonus: --
Christopher Haqq
Executive Vice President - Research and Development, Chief Scientific Officer, Since 2012
Salary: $416,000.00
Bonus: $154,752.00
Heather Turner
Executive Vice President, General Counsel, Secretary and Head of Portfolio Strategy, Since 2015
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

611 Gateway Blvd Ste 900
SOUTH SAN FRANCISCO   CA   94080-7015

Phone: +1650.2788930

Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells. T-cells are a type of white blood cell. The Company's product candidate, ATA129, is a third-party derived Epstein-Barr virus CTL for the treatment of Epstein-Barr virus (EBV). ATA188 is in development for the treatment of multiple sclerosis. ATA520, which is a third-party donor derived WT1-CTL, targets cancers expressing the antigen Wilms Tumor 1 (WT1). ATA520 is in Phase I clinical trials. The Company's T-cell product candidate, ATA230, which is a third-party derived cytomegalovirus-CTL (CMV-CTL), is in Phase II clinical trials for refractory CMV.

SPONSORED STORIES